The availability of large neutral amino acids in brain cells is crucial to the regulation of both cerebral protein metabolism and neurotransmitter synthesis. The transport of circulating amino acids from blood to brain involves transport through two membranes in series: (i) the brain capillary endothelial wall, which makes up the blood-brain barrier (BBB) in vivo, and (ii) the brain cell (neuron, glial) plasma membrane. Since the surface area of the brain cell membrane is log orders greater than the surface area of the blood-brain barrier, the rate limiting step in amino acid movement from plasma to brain intracellular space is the BBB transport step. This work will study the pathophysiological expression of the large neutral amino acid transporter (LAT) at the blood-brain barrier. The preliminary data show that the full length LAT-cDNA encodes a protein that expresses LAT activity in frog oocytes. Antisera will be produced with synthetic peptides encoding either the carboxyl terminus or predicted extracellular domains of the bovine BBB LAT. The abundance and cellular localization of this transporter will be studied by Western blotting, ELISA, in situ hybridization, immunocytochemistry, and confocal and immunogold electron microscopy, respectively. The modulation of gene expression of BBB LAT will be studied under different pathophysiologic conditions known to modify the transporter activity, i.e. brain tumors, development, hypothyroidism and hypoxia. The mechanisms of gene regulation of BBB LAT will be investigated in brain endothelial cultured cells measuring the abundance of its protein and transcript, and the transcriptional rate and decay of the BBB LAT mRNA. The cloning of cDNAs encoding the rabbit BBB LAT will also be performed. Because the in vivo Km for the BBB LAT markedly differs among species (i.e. human BBB < rat BBB < rabbit BBB), comparison of the predicted amino acid sequence of BBB LAT from these 3 species will provide insight into the amino acids comprising the active site of the LAT protein, which will be confirmed by site-directed mutagenesis studies. These studies will provide new molecular biological information on a crucial transporter at the blood-brain barrier that regulates the supply in the brain of essential amino acids.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS040016-01A1
Application #
6261421
Study Section
Special Emphasis Panel (ZRG1-BDCN-3 (01))
Program Officer
Jacobs, Tom P
Project Start
2000-09-30
Project End
2004-08-31
Budget Start
2000-09-30
Budget End
2001-08-31
Support Year
1
Fiscal Year
2000
Total Cost
$229,500
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Boado, Ruben J; Li, Jian Yi; Chu, Chun et al. (2005) Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1. Biochim Biophys Acta 1715:104-10
Boado, Ruben J; Li, Jian Yi; Pardridge, William M (2004) Developmental regulation of the rabbit blood-brain barrier LAT1 large neutral amino acid transporter mRNA and protein. Pediatr Res 55:557-60
Boado, Ruben J; Li, Jian Yi; Wise, Petra et al. (2004) Human LAT1 single nucleotide polymorphism N230K does not alter phenylalanine transport. Mol Genet Metab 83:306-11
Boado, Ruben J; Li, Jian Yi; Pardridge, William M (2003) Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234. J Neurochem 84:1322-31
Boado, Ruben J; Li, Jian Yi; Tsukamoto, Haruhisa et al. (2003) Hypoxia induces de-stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cells. J Neurochem 85:1037-42